Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Market Forecasts by DelveInsight Signal Groundbreaking Growth by 2032 | UCB Biopharma (Bimekizumab)

As per DelveInsight, the Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Market is anticipated to evolve immensely in the coming years owing to the expected launch of emerging therapies. With increasing prevalence and awareness of the disease, more companies focus on the upcoming therapeutic pipeline of Nr-AxSpA.

DelveInsight's "Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Non-Radiographic Axial Spondyloarthritis Market Size and Share in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The market report covers emerging drugs, treatment practices, market share of individual Non-Radiographic Axial Spondyloarthritis therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Non-Radiographic Axial Spondyloarthritis treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.

Non-Radiographic Axial Spondyloarthritis (nr-AxSpA): An Overview
Non-radiographic axial Spondyloarthritis (Nr-AxSpA) belongs to the axial spondyloarthritis (axSpA) family of inflammatory conditions. These conditions affect the spine and SI joints, but signs and symptoms can occur in other parts of the body.

Nr-axSpA is a long-term inflammatory disease. In this disease, the immune system turns on itself and attacks healthy tissue in the joints. Experts don't know what causes it. But they think genetics may play a role. About 85% of people with the disease have a gene called HLA-B27. HLA-B27 is often a sign of problems with the immune system, your body's defense against germs.

The condition affects the joints and the entheses -- tissues that connect bones to ligaments or tendons. With nr-axSpA, even though the person might have symptoms, X-rays don't show any damage to the joints.

Nr-AxSpA is characterized by the absence of definitive x-ray evidence of structural damage to the sacroiliac (SI) joint by plain x-ray. Since the SI joint x-ray interpretation is subjective, the distinction between Nr-AxSpA and AS is not absolute. Sacroiliitis (inflammation of the SI joint) and inflammation of the spine are predominant features of AxSpA; hence patients typically present with inflammatory back pain.

Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Market Key Facts
• In 2022, the total prevalent cases of Nr-AxSpA were ~1,708,000 in the 7MM. These cases are anticipated to increase during the forecast period [2023-2032].
• Among EU4 countries, France accounted for the least number of total diagnosed prevalent cases of Nr-AxSpA , which were ~54,000 in 2022.
• In 2022, Japan had ~900 diagnosed prevalent cases for Nr-AxSpA. These cases are anticipated to increase by 2032.
• On the basis of gene-specific diagnosed prevalence of Nr-AxSpA, HLA-B27 accounted ~74% cases in Germany, whereas, ERAP 1, IL-12, IL-17, and IL-23 accounted for ~26% of the cases in 2022

Get a Detailed Overview of the Evolving Non-Radiographic Axial Spondyloarthritis Market Trends @
https://www.delveinsight.com/report-store/non-radiographic-axial-spondyloarthritis-nr-axspa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Non-Radiographic Axial Spondyloarthritis therapies in the market. It also provides a detailed assessment of the Non-Radiographic Axial Spondyloarthritis market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete details of the market trend for each marketed Non-Radiographic Axial Spondyloarthritis drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MOA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Discover How the Non-Radiographic Axial Spondyloarthritis Market Will Grow by 2032 @
https://www.delveinsight.com/report-store/non-radiographic-axial-spondyloarthritis-nr-axspa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Epidemiology
The epidemiology section covers detailed insights into the historical, and current Non-Radiographic Axial Spondyloarthritis patient pool and forecasted epidemiology trends for every seven major countries (7MM) from 2019 to 2032.

The Report Covers the Non-Radiographic Axial Spondyloarthritis Epidemiology Segmented as -
• Total Prevalent Cases of Non-radiographic Axial Spondyloarthritis (Nr-AxSpA) in the 7MM [2019-2032]
• Total Diagnosed Prevalent Cases of Non-radiographic Axial Spondyloarthritis (Nr-AxSpA) in the 7MM [2019-2032]
• Gender-specific Diagnosed Prevalent Cases of Non-radiographic Axial Spondyloarthritis (Nr-AxSpA) in the 7MM [2019-2032]
• Gene-specific Diagnosed Prevalent Cases of Non-radiographic Axial Spondyloarthritis (Nr-AxSpA) in the 7MM [2019-2032]

Get Key Insights Into the Evolving Non-Radiographic Axial Spondyloarthritis Epidemiology Trends @
https://www.delveinsight.com/sample-request/non-radiographic-axial-spondyloarthritis-nr-axspa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Drugs Uptake and Pipeline Development Activities
The drugs' uptake section focuses on the rate of uptake of the potential drugs recently launched in the Non-Radiographic Axial Spondyloarthritis market or expected to be launched during the study period. The analysis covers the market share by Non-Radiographic Axial Spondyloarthritis drugs, patient uptake by therapies, and sales of each drug.

The report's drugs uptake section helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs. It allows the comparison of the drugs based on market share and size, which again will be helpful in investigating factors important in understanding the market dynamics and in making financial and regulatory decisions.

The report also covers the Non-Radiographic Axial Spondyloarthritis Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Explore More About Ongoing Pipeline Development Activities in the Non-Radiographic Axial Spondyloarthritis Market @
https://www.delveinsight.com/sample-request/non-radiographic-axial-spondyloarthritis-nr-axspa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Therapeutics Assessment
Treatments for Nr-AxSpA may comprise physical therapy and NSAIDs. Additionally, doctors may recommend biologic drugs called TNF inhibitors that help to reduce inflammation. One of the main symptoms of Nr-AxSpA is back pain due to inflammation. The pain differs from those of mechanical back pain because it often begins in late adolescence or early adulthood and may improve rather than worsen with physical activity.

Treatment for Nr-AxSpA usually starts with nonsteroidal anti-inflammatory drugs (NSAIDs), physical therapy, and exercise. As long as the disease is not too advanced, NSAIDs and regular movement are usually enough to keep things under control. Three drugs (Cimzia, Taltz and Cosentyx) are approved by the FDA to treat Nr-axSpA. Recently, Rinvoq was also approved in 2022 to treat Nr-AxSpA in adults.

In October 2022, US FDA approved RINVOQ (upadacitinib 15 mg, once daily), an oral therapy, for the treatment of adults with active non-radiographic axial spondyloarthritis (Nr-AxSpA) with objective signs of inflammation who have had an inadequate response or intolerance to tumor necrosis factor (TNF) blocker therapy.

Currently, UCB Biopharma is leading the Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Therapeutics Market with its therapy, Bimekizumab. Bimekizumab is the first humanized monoclonal IgG1 antibody that potently and selectively neutralizes IL-17A and IL-17F. These are the two key pro-inflammatory cytokines that share similar biological function and structural homology. IL-17A and IL-17F are the most closely related members of the IL-17 family of cytokines. They are both co-expressed at sites of inflammation and have overlapping pro-inflammatory functions. Both IL-17A and IL-17F can independently cooperate with other inflammatory mediators to drive chronic inflammation and tissue destruction. This therapeutic candidate is in the Phase III stage of development to treat patients with AS. The company is using the subcutaneous route of administration for treatment of AS and Nr-AxSpA.

Learn More About the Emerging Therapies and key Companies in the Non-Radiographic Axial Spondyloarthritis Therapeutics Market @
https://www.delveinsight.com/sample-request/non-radiographic-axial-spondyloarthritis-nr-axspa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Non-Radiographic Axial Spondyloarthritis Competitive Intelligence Analysis
4. Non-Radiographic Axial Spondyloarthritis Market Overview at a Glance
5. Non-Radiographic Axial Spondyloarthritis Background and Overview
6. Non-Radiographic Axial Spondyloarthritis Patient Journey
7. Non-Radiographic Axial Spondyloarthritis Epidemiology and Patient Population
8. Non-Radiographic Axial Spondyloarthritis Treatment Algorithm, Current Treatment, and Medical Practices
9. Non-Radiographic Axial Spondyloarthritis Unmet Needs
10. Key Endpoints of Non-Radiographic Axial Spondyloarthritis Treatment
11. Non-Radiographic Axial Spondyloarthritis Marketed Products
12. Non-Radiographic Axial Spondyloarthritis Emerging Therapies
13. Non-Radiographic Axial Spondyloarthritis Seven Major Market Analysis
14. Attribute Analysis
15. Non-Radiographic Axial Spondyloarthritis Market Outlook (7 major markets)
16. Non-Radiographic Axial Spondyloarthritis Access and Reimbursement Overview
17. KOL Views on the Non-Radiographic Axial Spondyloarthritis Market.
18. Non-Radiographic Axial Spondyloarthritis Market Drivers
19. Non-Radiographic Axial Spondyloarthritis Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.

Download the Sample PDF to Get Detailed Insights About the Report's Offerings @
https://www.delveinsight.com/sample-request/non-radiographic-axial-spondyloarthritis-nr-axspa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

------------------------------------------------------------------------------------------------------------------------------
Discover DelveInsight's Comprehensive Market Research and Consulting Services:
https://www.delveinsight.com/market-research

Elevate your industry insights with our comprehensive medical devices market assessment reports. Visit to gain a strategic edge through expert analysis and in-depth coverage of the latest trends, innovations, and market dynamics, at:
https://www.delveinsight.com/medical-devices

Empowering Cancer Care: DelveInsight's oncology consulting services offer personalized guidance and cutting-edge expertise to navigate the ongoing clinical, commercial, and regulatory developments, visit for more details:
https://www.delveinsight.com/oncology

Other Trending Healthcare Reports by DelveInsight
Acute Ocular Pain Market
https://www.delveinsight.com/report-store/acute-ocular-pain-market

Acute On Chronic Liver Failure (ACLF) Market
https://www.delveinsight.com/report-store/acute-on-chronic-liver-failure-aclf-market

Antibody-Mediated Graft Rejection Market
https://www.delveinsight.com/report-store/antibody-mediated-graft-rejection-market

Bacterial (Pyogenic) Meningitis Market
https://www.delveinsight.com/report-store/bacterial-pyogenic-meningitis-market

Bevacizumab Biosimilars
https://www.delveinsight.com/report-store/bevacizumab-biosimilars-insight

Bronchial Neoplasm Market
https://www.delveinsight.com/report-store/bronchial-neoplasm-market

Calcinosis Cutis Market
https://www.delveinsight.com/report-store/calcinosis-cutis-market

Cardiovascular Calcification Market
https://www.delveinsight.com/report-store/cardiovascular-calcification-market

Dermal Regeneration Matrix Market
https://www.delveinsight.com/report-store/dermal-regeneration-matrix-market

Epstein Barr virus (EBV) Market
https://www.delveinsight.com/report-store/epstein-barr-virus-ebv-market

Glabellar Frown Lines Market
https://www.delveinsight.com/report-store/glabellar-frown-lines-market

Goitre Market
https://www.delveinsight.com/report-store/goitre-market

Hereditary Deafness Medical Device Market
https://www.delveinsight.com/report-store/hereditary-deafness-medical-devices-market

ICOS-Next Generation Immunotherapy Market
https://www.delveinsight.com/report-store/icos-next-generation-immunotherapy-competitive-landscape

Metrorrhagia Market
https://www.delveinsight.com/report-store/metrorrhagia-market

Nephrosclerosis Market
https://www.delveinsight.com/report-store/nephrosclerosis-market

Parkinson's Disease Related Dementia Market
https://www.delveinsight.com/report-store/parkinsons-disease-related-dementia-market

Peripherally Inserted Central Catheter (PICC) Devices Market
https://www.delveinsight.com/report-store/peripherally-inserted-central-catheter-picc-devices-market

Severe Toxicities in Lymphoma Market
https://www.delveinsight.com/report-store/severe-toxicities-in-lymphoma

Single Ventricle Heart Disease Market
https://www.delveinsight.com/report-store/single-ventricle-heart-disease-market

Small Fiber Neuropathy Market
https://www.delveinsight.com/report-store/small-fiber-neuropathy-market

Stuttering Market
https://www.delveinsight.com/report-store/stuttering-market

Venous Stenosis Market
https://www.delveinsight.com/report-store/venous-stenosis-market

Hyperopia Market
https://www.delveinsight.com/report-store/hyperopia-market

Microvascular Angina Market
https://www.delveinsight.com/report-store/microvascular-angina-market

Progressive Familial Intrahepatic Cholestasis Market
https://www.delveinsight.com/report-store/progressive-familial-intrahepatic-cholestasis-pfic-market

CRISPR Therapies Pipeline Insight
https://www.delveinsight.com/report-store/crispr-therapies-pipeline-insight

Endometrial Hyperplasia Market
https://www.delveinsight.com/report-store/endometrial-hyperplasia-market

Adenoid Cystic Carcinoma Market
https://www.delveinsight.com/report-store/adenoid-cystic-carcinom-market

Chronic Pain Associated with Painful Diabetic Neuropathy Market
https://www.delveinsight.com/report-store/chronic-pain-associated-with-painful-diabetic-neuropathy-market

Contact Dermatitis Market
https://www.delveinsight.com/report-store/contact-dermatitis-market

Dermal Mycosis Market
https://www.delveinsight.com/report-store/dermal-mycosis-market

High-Grade Glioma Market
https://www.delveinsight.com/report-store/high-grade-glioma-hgg-market

Lymphatic Malformations Market
https://www.delveinsight.com/report-store/lymphatic-malformations-market

Nocturnal Enuresis Market
https://www.delveinsight.com/report-store/nocturnal-enuresis-market

Ulcer Haemorrhage Market
https://www.delveinsight.com/report-store/ulcer-haemorrhage-market

Adult-onset Still Disease Market
https://www.delveinsight.com/report-store/adult-onset-still-disease-market

Alcohol Use Disorder (AUD) Market
https://www.delveinsight.com/report-store/alcohol-use-disorder-market

Cell And Gene Therapy For Multiple Myeloma Market
https://www.delveinsight.com/report-store/cell-and-gene-therapy-for-multiple-myeloma-market

Chronic Pancreatitis (CP) Market
https://www.delveinsight.com/report-store/chronic-pancreatitis-market

Cough in Idiopathic Pulmonary Fibrosis (IPF) Market
https://www.delveinsight.com/report-store/cough-in-idiopathic-pulmonary-fibrosis-ipf-market

End-Stage Coronary Artery Disease Market
https://www.delveinsight.com/report-store/end-stage-coronary-artery-disease-market

Frontotemporal Dementia Market
https://www.delveinsight.com/report-store/frontotemporal-dementia-market

Cell and Gene Therapies in Rare Disorders Market
https://www.delveinsight.com/report-store/gene-and-cell-therapies-in-rare-disorder-market

Glycogen Storage Disease Market
https://www.delveinsight.com/report-store/glycogen-storage-disease-market

Maple Syrup Urine Disease Market
https://www.delveinsight.com/report-store/maple-syrup-urine-disease-market

MELAS Syndrome Market
https://www.delveinsight.com/report-store/melas-syndrome-market

Contact Info:
Shruti Thakur
Manager (Marketing & Branding)
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.